As President of Parallel 33 Consulting, Inc., Ron provides professional scientific and regulatory advice in clinical pharmacology, toxicology, and DMPK in drug development to support the safe and effective use of pharmaceutical products as specified by IND, BLA, and NDA requirements. His principal strengths include directing and managing nonclinical/early clinical development activities supporting development of small molecules, protein conjugates, monoclonal antibodies, cellular therapies, infectious disease and gene therapies in the pharmaceutical industry as an independent consultant.
Ron has over 30 years’ experience in the pharmaceutical and biotech industries with extensive experience in pharmaceutical (small molecule and biotherapeutics) research and development. He received his doctorate in Veterinary Toxicology from Texas A&M University and is a Diplomate of the American Board of Toxicology (2003) and Fellow, American College of Clinical Pharmacology (2011). In his most recent role, he was Vice President, Drug Development at Arena Pharmaceuticals, Inc. (San Diego, CA) and was responsible for drug safety, drug disposition and early clinical development activities supporting metabolic, cardiovascular, CNS and autoimmune therapeutic areas. Prior to joining Arena Pharmaceuticals, Ron has served in various management roles within the research and development industry, to include Takeda Pharmaceuticals, Johnson & Johnson, Schering-Plough, Bayer, and Ligand Pharmaceuticals. Ron has supported with teaching at the University of California, San Diego Skaggs School of Pharmacy in an adjunct professor role and has published more than 75 original peer-reviewed publications, conference abstracts and chapters in the areas of pharmacology, drug metabolism, pharmacokinetics, exposure-response modeling, biopharmaceutics, and drug-drug interactions in therapeutic areas of oncology, CNS, inflammation and metabolic research. Ron holds a B.S. in pathobiology from The University of Connecticut (Storrs).